MEK Inhibitor–Induced Dusky Erythema: Characteristic Drug Hypersensitivity Manifestation in 3 Patients

Importance  MEK inhibitors are being evaluated in clinical trials for treatment of different malignant neoplasms; trametinib dimethyl sulfoxide was approved by the US Food and... »

Source: JAMA Oncology - December 4, 2014 Category: Cancer & Oncology Authors: Urvi Patel, MD and colleagues Tags: Case Report/Case Series Clinical Review & Education JAMA Dermatology Source Type: research